GSK’s treatment for chronic hepatitis B delivered a positive result in two late-stage trials and could provide a cure for a condition that affects more than 250mn people.
The British drugmaker said on Wednesday that its phase 3 trials of bepirovirsen delivered a “statistically significant and clinically meaningful functional cure rate” in the more than 1,800 patients from 29 countries who participated in the two studies.
Functional cure rates, defined as when the virus can no longer be detected in patients’ blood, were significantly higher with bepirovirsen plus standard of care, compared with standard of care alone, the company said.
您已阅读27%（640字），剩余73%（1693字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。